共 50 条
- [21] Small-Volume, 6-Month Subcutaneous Leuprolide Acetate Effectively Suppresses Estradiol and Testosterone to Very Low Levels in Patients with Central Precocious Puberty HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 1): : 135 - 136
- [22] Two years of clinical experience with six month subcutaneous leuprolide acetate for central precocious puberty JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES, 2024, 77 : 241 - 242
- [24] EFFICACY OF LEUPROLIDE THERAPY IN CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1988, 142 (10): : 1061 - 1064
- [26] 36-Month Treatment Experience of Two Doses of Leuprolide Acetate 3-Month Depot for Children With Central Precocious Puberty JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (09): : 3153 - 3159
- [28] 2-YEAR RESULTS OF TREATMENT WITH DEPOT LEUPROLIDE ACETATE FOR CENTRAL PRECOCIOUS PUBERTY JOURNAL OF PEDIATRICS, 1992, 121 (04): : 634 - 640
- [29] Phase 3 Trial of a Small-Volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty (vol 105, pg e3660, 2020) JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (07): : E2842 - E2842
- [30] Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2016, 29 (11): : 1249 - 1257